By pinpointing the Golgi and postsynaptic sites and revealing astrocyte buffering of manganese, the work identifies cell-type and subcellular targets relevant to manganese-induced parkinsonism and suggests avenues for targeted neuroprotective strategies against environmental metal neurotoxicity.

The finding that cognitive domains in PD are temporally dynamic highlights the need to rethink diagnostic criteria, endpoint selection, and patient stratification in trials—potentially improving biomarker and clinical outcome design—though it offers little direct mechanistic or therapeutic targets.

Improved uptake of genetic testing enhances patient identification for genotype-stratified trials and precision-medicine approaches, but the study offers limited direct mechanistic or therapeutic insights.

While not revealing molecular targets, this identifies modifiable affective contributors and measurement considerations that could inform symptomatic treatments, patient selection, and outcome measures in PD trials.

This low-cost, portable platform enables point-of-care monitoring of GSH as an oxidative-stress biomarker relevant to Parkinson’s disease patient monitoring and stratification, but it offers limited direct mechanistic or therapeutic-discovery insights.

The work highlights oligodendrocyte/MOBP dysregulation as a shared neurodegeneration signal and a possible biomarker/target, but provides limited direct, PD-specific mechanistic or therapeutic leads for Parkinson's drug discovery.

If confirmed in larger cohorts, hearing impairment could serve as an early, potentially modifiable risk marker for Parkinson's disease dementia, informing screening and prevention strategies, but current findings are exploratory and underpowered.

Offers a language-specific, speaker-robust speech biomarker and feature-selection pipeline useful for remote staging and monitoring in PD clinical assessments and trials, but it provides little mechanistic or therapeutic discovery insight.

Direct therapeutic relevance to Parkinson's is limited, but the demonstrated ability to synthesize missing MRI contrasts (validated on PPMI data) can help recover incomplete imaging datasets and enable quantitative biomarker or longitudinal imaging studies in PD research.

Direct therapeutic relevance to Parkinson's is limited, but the approach—inferring cell-autonomous genetic/pathologic states from transcriptomic signatures—could be adapted to identify PD-relevant cellular states or biomarkers at single-cell resolution.

Useful for public-health prioritization, trial site and recruitment planning, and identifying high-burden regions and demographic groups for PD interventions, but offers minimal mechanistic or translational insights for direct therapeutic discovery.

Valuable for health-policy and care-planning by documenting a growing Parkinson's rehabilitation burden in China, but it provides little mechanistic insight or direct therapeutic targets for drug discovery.

This paper has minimal relevance for Parkinson's therapeutic discovery because it is a cardiology case report without mechanistic, biomarker, or neurodegeneration insights, though it may inform clinicians about pregnancy-specific drug and management considerations that could intersect with comorbid…

Highlights epigenetic alterations as candidate biomarkers and targetable pathways that could inform earlier Parkinson's diagnosis and epigenetic-based interventions, but is a broad, non-Parkinson-specific review with limited immediate actionable therapeutic leads.

Identifies peripheral inflammation as a prognostic biomarker and a translationally relevant pathway that could guide patient stratification and testing of anti-inflammatory or immunomodulatory therapies, though observational design limits causal inference.

Although this is a correction rather than new data, the underlying review concerns bright light therapy—a low-risk, repurposable intervention targeting sleep/circadian dysfunction relevant to PD non-motor symptoms and clinical trial design.

While primarily epidemiological, the region-specific carrier frequencies—especially enrichment of PLA2G6 variants linked to parkinsonism and iron dysregulation—help prioritize genetic screening, patient identification, and follow-up studies of iron-related mechanisms that could inform…

Low direct value for Parkinson's drug discovery, but the case highlights infection-triggered nigral dysfunction and an imaging correlate that could inform studies of secondary parkinsonism and mechanisms of nigral vulnerability.

The retraction means the reported connectivity-based predictor and its implications for DBS-guided treatment of sleep symptoms in PD are unreliable and should not inform therapeutic decisions, though the topic (sleep outcomes and biomarkers for DBS) remains clinically relevant for future valid…

The study presents a brain-targetable, degradation-resistant antioxidant/anti-inflammatory compound with translational potential (intranasal delivery and Nrf2-related mechanism) that could be advanced for neuroprotective PD strategies, though validation in alpha-synuclein models and…